Annual report of Trident Lifeline Limited for the FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Trident Lifeline Limited has filed its 12th AGM notice and Annual Report for FY 2024-25 with BSE. The AGM is scheduled for September 27, 2025 at 4:00 PM via video conferencing, with the cut-off date for e-voting eligibility set as September 19, 2025 and remote e-voting window from September 24-26, 2025. The annual report highlights a strong FY25 with total revenue jumping 51% to ₹7,094 lakhs (from ₹4,686 lakhs in FY24). EBITDA surged 87% to ₹2,066 lakhs and Profit After Tax nearly doubled (up 85%) to ₹1,305 lakhs. EBITDA margin expanded from 24% to 29%, while ROE stood at 26%. During the year, the company commissioned its TNS Pharma subsidiary's manufacturing facility, incorporated TLL Elements (100% wholly owned) for skin and hair care, and acquired 51% stakes in TLL Parenterals (injectables) and Trident Mediquip (medical devices). The company also partnered with NIPER Ahmedabad for technology transfer of Vorinostat, a CTCL medication. TLL operates in 43 countries with 1,021 export product registrations (2,225 in process), and holds a portfolio of 3,246 products across 16 therapeutic segments.
This is a routine AGM notice filing, but the underlying annual report shows significant business momentum — revenue, EBITDA, and PAT all grew 50%+ year-on-year with margin expansion. For shareholders, the strong FY25 performance and aggressive acquisition-led growth strategy (injectables, medical devices, skincare) signal a scaling-up phase. Investors should watch the AGM for management commentary on integration of new subsidiaries and FY26 guidance.